StockNews.com began coverage on shares of Pulmatrix (NASDAQ:PULM – Get Free Report) in a report issued on Wednesday. The firm set a “hold” rating on the biotechnology company’s stock.
Pulmatrix Price Performance
Shares of PULM opened at $1.92 on Wednesday. The firm has a fifty day moving average price of $1.94 and a 200 day moving average price of $1.89. The stock has a market cap of $7.01 million, a PE ratio of -0.80 and a beta of 0.94. Pulmatrix has a 1-year low of $1.55 and a 1-year high of $2.88.
Pulmatrix (NASDAQ:PULM – Get Free Report) last announced its earnings results on Friday, May 10th. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter. The firm had revenue of $5.89 million during the quarter. Pulmatrix had a negative return on equity of 44.05% and a negative net margin of 75.73%.
About Pulmatrix
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Featured Articles
- Five stocks we like better than Pulmatrix
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Occidental Stock: Buffett’s 9-Day Buying Spree Lifts Stake to 29%
- Business Services Stocks Investing
- 3M Stock: Invest Now for Unmatched Quality and Growth Potential
- Trading Stocks: RSI and Why it’s Useful
- Super Micro AI Stock: Should You Invest After a 275% Increase?
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
